CN105828642A - 包含蔗糖铁和高浓度微胶囊包封的lc-pufa且异味减弱的组合物 - Google Patents
包含蔗糖铁和高浓度微胶囊包封的lc-pufa且异味减弱的组合物 Download PDFInfo
- Publication number
- CN105828642A CN105828642A CN201480069674.5A CN201480069674A CN105828642A CN 105828642 A CN105828642 A CN 105828642A CN 201480069674 A CN201480069674 A CN 201480069674A CN 105828642 A CN105828642 A CN 105828642A
- Authority
- CN
- China
- Prior art keywords
- compositions
- pufa
- present
- weight
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 238
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 title claims abstract description 87
- 235000008824 ferric saccharate Nutrition 0.000 title abstract 2
- 239000011788 ferric saccharate Substances 0.000 title abstract 2
- XRDYWGSODBNAIE-BQGRAUOOSA-K iron(3+);(2r,3s,4s,5s)-2,3,4,5,6-pentahydroxy-6-oxohexanoate Chemical compound [Fe+3].OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O XRDYWGSODBNAIE-BQGRAUOOSA-K 0.000 title abstract 2
- 235000019640 taste Nutrition 0.000 title description 20
- 238000000034 method Methods 0.000 claims abstract description 43
- 235000016709 nutrition Nutrition 0.000 claims abstract description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 15
- 230000035764 nutrition Effects 0.000 claims abstract description 15
- 239000008103 glucose Substances 0.000 claims abstract description 14
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 12
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 11
- 230000036541 health Effects 0.000 claims abstract description 9
- 239000002516 radical scavenger Substances 0.000 claims abstract description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 44
- 239000000796 flavoring agent Substances 0.000 claims description 41
- 239000000047 product Substances 0.000 claims description 41
- 235000019634 flavors Nutrition 0.000 claims description 39
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 claims description 32
- 230000002159 abnormal effect Effects 0.000 claims description 30
- 229940032961 iron sucrose Drugs 0.000 claims description 28
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 23
- 235000019197 fats Nutrition 0.000 claims description 21
- 235000019198 oils Nutrition 0.000 claims description 19
- 235000013305 food Nutrition 0.000 claims description 18
- 230000003647 oxidation Effects 0.000 claims description 18
- 238000007254 oxidation reaction Methods 0.000 claims description 18
- 102000014171 Milk Proteins Human genes 0.000 claims description 16
- 108010011756 Milk Proteins Proteins 0.000 claims description 16
- 235000021239 milk protein Nutrition 0.000 claims description 16
- 235000021323 fish oil Nutrition 0.000 claims description 15
- 235000010443 alginic acid Nutrition 0.000 claims description 12
- 229920000615 alginic acid Polymers 0.000 claims description 12
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 11
- 229940072056 alginate Drugs 0.000 claims description 11
- 235000006708 antioxidants Nutrition 0.000 claims description 11
- 229930003427 Vitamin E Natural products 0.000 claims description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 9
- 235000019165 vitamin E Nutrition 0.000 claims description 9
- 239000011709 vitamin E Substances 0.000 claims description 9
- 229940046009 vitamin E Drugs 0.000 claims description 9
- 230000000968 intestinal effect Effects 0.000 claims description 8
- 229940123457 Free radical scavenger Drugs 0.000 claims description 7
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims description 5
- 229930003799 tocopherol Natural products 0.000 claims description 5
- 229960001295 tocopherol Drugs 0.000 claims description 5
- 235000010384 tocopherol Nutrition 0.000 claims description 5
- 239000011732 tocopherol Substances 0.000 claims description 5
- 241000195493 Cryptophyta Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- 208000002720 Malnutrition Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 230000001071 malnutrition Effects 0.000 claims description 3
- 235000000824 malnutrition Nutrition 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 239000003094 microcapsule Substances 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 3
- 238000005728 strengthening Methods 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 230000018109 developmental process Effects 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 230000008271 nervous system development Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 230000004491 retinal development Effects 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 235000009508 confectionery Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 235000021003 saturated fats Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 34
- 108090000623 proteins and genes Proteins 0.000 abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 21
- 201000010099 disease Diseases 0.000 abstract description 20
- 239000011159 matrix material Substances 0.000 abstract description 3
- 230000007935 neutral effect Effects 0.000 abstract description 2
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 235000013365 dairy product Nutrition 0.000 abstract 1
- 230000008774 maternal effect Effects 0.000 abstract 1
- 229940057917 medium chain triglycerides Drugs 0.000 abstract 1
- 239000002417 nutraceutical Substances 0.000 abstract 1
- 235000021436 nutraceutical agent Nutrition 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 33
- 239000003921 oil Substances 0.000 description 15
- 239000000839 emulsion Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 239000003973 paint Substances 0.000 description 13
- 102000004407 Lactalbumin Human genes 0.000 description 12
- 108090000942 Lactalbumin Proteins 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000003995 emulsifying agent Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 10
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 10
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 10
- 235000013336 milk Nutrition 0.000 description 10
- 239000008267 milk Substances 0.000 description 10
- 210000004080 milk Anatomy 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 229940088594 vitamin Drugs 0.000 description 10
- 229930003231 vitamin Natural products 0.000 description 10
- 235000013343 vitamin Nutrition 0.000 description 10
- 239000011782 vitamin Substances 0.000 description 10
- 150000003722 vitamin derivatives Chemical class 0.000 description 10
- 241000251468 Actinopterygii Species 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 9
- 235000014633 carbohydrates Nutrition 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000035943 smell Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 235000020995 raw meat Nutrition 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000013406 prebiotics Nutrition 0.000 description 5
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- -1 Isosorbide Dinitrate Chemical class 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000011785 micronutrient Substances 0.000 description 4
- 235000013369 micronutrients Nutrition 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 208000027219 Deficiency disease Diseases 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 241000605909 Fusobacterium Species 0.000 description 3
- 240000000111 Saccharum officinarum Species 0.000 description 3
- 235000007201 Saccharum officinarum Nutrition 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002366 mineral element Substances 0.000 description 3
- 230000000050 nutritive effect Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 241000193798 Aerococcus Species 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 241000192041 Micrococcus Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 241000235395 Mucor Species 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000192001 Pediococcus Species 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 241000186429 Propionibacterium Species 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 229940071162 caseinate Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000019488 nut oil Nutrition 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000003346 palm kernel oil Substances 0.000 description 2
- 235000019865 palm kernel oil Nutrition 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 1
- FLISWPFVWWWNNP-UHFFFAOYSA-N 3-oct-1-enyloxolane-2,5-dione Chemical compound CCCCCCC=CC1CC(=O)OC1=O FLISWPFVWWWNNP-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 229920000310 Alpha glucan Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 241000235035 Debaryomyces Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 241001468189 Melissococcus Species 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000202223 Oenococcus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 241001489223 Saccharomycodes Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 241000202221 Weissella Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- ZKLLSNQJRLJIGT-UYFOZJQFSA-N keto-D-fructose 1-phosphate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)COP(O)(O)=O ZKLLSNQJRLJIGT-UYFOZJQFSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 125000002640 tocopherol group Chemical group 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/02—Other edible oils or fats, e.g. shortenings, cooking oils characterised by the production or working-up
- A23D9/04—Working-up
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/06—Preservation of finished products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及组合物,优选为营养组合物,优选地用于婴儿、儿童、孕产妇、衰老保健、中老年人或医疗保健营养。本发明还涉及药物组合物和/或营养组合物。本文所述的本发明组合物优选地具有中性或酸性pH,优选地pH范围为约3至约7.5,所述组合物中加入了高浓度蔗糖铁和高浓度微胶囊包封的长链多不饱和脂肪酸(LC?PUFA),优选地被微胶囊包封在乳品蛋白和葡萄糖的玻璃状基质中。优选地,本发明的组合物还包含为自由基清除剂的抗氧化剂,优选地带有非敏感性油,所述油最优选地包含中链甘油三酯。本发明还描述了用于制备这类组合物的方法以及这类组合物的用途,所述这类组合物优选地用于治疗如本文所定义的疾病。
Description
技术领域
本发明涉及组合物,优选为营养组合物,优选地用于婴儿、儿童、孕产妇、衰老保健、中老年人或医疗保健营养。本发明还涉及药物组合物和/或营养组合物。
本文所述的本发明组合物优选地具有中性或酸性pH,优选地pH范围为约3至约7.5,所述组合物用蔗糖铁和高浓度微胶囊包封的长链多不饱和脂肪酸(LC-PUFA)强化,优选地被微胶囊包封在乳品蛋白和葡萄糖的玻璃状基质中。优选地,本发明的组合物还包含作为自由基清除剂的抗氧化剂,优选地带有非敏感性油并且更优选地带有蛋白质,所述油最优选地包含中链甘油三酯,并且所述蛋白质最优选地包含乳清。
本发明的组合物还包含所述微胶囊包封的LC-PUFA和微胶囊包封的蔗糖铁,优选地其中后者被微胶囊包封在藻酸盐基质中。
本发明的组合物优选地具有改善的感官特性,最优选地具有减弱的异味,甚至在存在高浓度蔗糖铁和微胶囊包封的LC-PUFA下也是如此。如果蔗糖铁也被微胶囊包封,本发明的组合物还可具有类似特性或甚至进一步改善的特性。也可包括如本文所定义的附加成分。
本发明还描述了用于制备这类组合物的方法以及这类组合物的用途。
背景技术
LC-PUFA是饮食中的必需组分,并且科学证据表明,特定LC-PUFA(例如二十二碳六烯酸(DHA)22:6n-3)对大脑和视网膜发育、心脏健康(二十碳五烯酸(EPA)22:5n-3)以及许多其他新兴的健康益处而言非常重要。
然而,由于LC-PUFA存在多个双键,因此在存在氧气,特别是存在铁时,LC-PUFA发生氧化。脂质氧化会通过风味和味道的劣化以及营养价值的降低来影响食品质量。诸如酸败、腥臭、金属味、油煎等异常风味和异常味道的形成主要来自于主要氧化产物(例如过氧化物)的降解,这类产物易于异构化并可降解生成挥发性化合物。感官特性的劣化是食品行业中消费者投诉的主要原因。此外,脂质氧化可显著影响货架期。
由于人们对于用能够带来显著营养益处的LC-PUFA强化食品的兴趣日益增长,已报告有许多工作在致力于开发能够降低因LC-PUFA氧化造成的降解和异味的技术,包括以下途径:
掩味剂和风味物
重点放在用于避免食品基质的腥臭异味的掩味剂和风味物上。然而,风味物和掩味剂不能使LC-PUFA稳定,因此所得的LC-PUFA氧化会导致营养价值下降。
工艺与包装
适当的工艺与包装也应降低食品基质中LC-PUFA的氧化速率,例如通过将LC-PUFA或铁与食品基质的其余部分分开。然而,该解决方案实在很昂贵并且不适用于每种类型的产品。
用于稳定LC-PUFA的成分,例如包封技术或特定抗氧化剂
这类解决方案中的一些是基于能够稳定LC-PUFA(例如包封技术或特定抗氧化剂)的成分。然而,这类解决方案优选地专门针对选定类型的食品基质,并且仅针对一种特定包封成分定制。
因此,本发明的一个目的是提供包含铁和高含量LC-PUFA的组合物且所述组合物具有减弱的异味。
本发明的另一个目的是提供具有改善的稳定性,优选地具有延长的货架期的组合物。
本发明的又一个目的是提供能够在液体或粉末产品中稳定LC-PUFA的组合物。
另一个目的是提供包含铁和高含量LC-PUFA的组合物用作药剂,优选地用于治疗需要高含量LC-PUFA的疾病。
还又一个目的是提供防止或降低LC-PUFA氧化的方法,所述方法优选地防止或减弱LC-PUFA的异味。
具体实施方式
如本文所述,本发明的目的优选地通过所附的独立权利要求项中的方法来完成。从属权利要求有利地示出本发明实施方案中更优选的方面。同样或甚至更优选的方面列于本说明中。
本发明的组合物基于成分的特定调整,其中本发明人惊奇地发现,本文中的本发明组合物中蔗糖铁和微胶囊包封的LC-PUFA的结合导致组合物的异味显著减弱,甚至其中含有蔗糖铁和高浓度微胶囊包封的LC-PUFA时也是如此。此外还有利的是,本发明包含优选被微胶囊包封的蔗糖铁。
本发明的组合物允许使用LC-PUFA和铁强化液体产品和/或粉末产品(从中性pH至酸性pH),同时使LC-PUFA氧化造成的异味尽可能低。这通过经过培训的专业小组在第二天品尝不同的基于乳剂的组合物后进行评估。特别地,品尝可在乳、乳产品(例如酸奶)和果汁产品中进行。
本文所用的术语“强化”是指,优选地使用本文所述的本发明方法向本发明的组合物或本领域的任何组合物中补充或加入在整体饮食中可能缺乏的营养物质。
因此,根据第一个实施方案,本发明的目的通过用蔗糖铁和高浓度微胶囊包封的LC-PUFA进行强化的组合物得到解决,所述组合物优选地具有改善的感官特性。
在本发明的上下文中,高浓度LC-PUFA优选地理解为通常占组合物约0.02重量%至10重量%,优选地占组合物约0.02重量%至5重量%的量。
根据一个同样优选的方面,微胶囊包封的LC-PUFA衍生自鱼油和/或藻油,优选地为DHA或EPA,或以鱼油和/或藻油的形式提供,优选地为DHA或EPA,以及最优选地为DHA和/或EPA。
本文所述的本发明的组合物还包含至少一种作为自由基清除剂的抗氧化剂,优选地为生育酚(维生素E)。更优选地,所述自由基清除剂占组合物约0.001重量%至约1重量%。
在本发明的一些方面,微胶囊包封的LC-PUFA被微胶囊包封在乳品蛋白和葡萄糖的玻璃状基质中。在本发明的一个优选方面中包含所述微胶囊包封的LC-PUFA和蔗糖铁,所述蔗糖铁也可被微胶囊包封,优选地被微胶囊包封在藻酸盐基质中。
在LC-PUFA被微胶囊包封在乳品蛋白和葡萄糖的玻璃状基质中的情况下,乳品蛋白的这种玻璃状基质可从任何可得且适用于此目的的乳品蛋白制备而成,例如乳清蛋白、酪蛋白、酪蛋白酸盐、乳蛋白、β-乳球蛋白、α-乳白蛋白等。包封可使用本领域已知的技术进行。优选地,如荷兰佛里斯兰品牌有限公司(Friesland Brands B.V.,NL)的WO 2011/008097 A1中所述,LC-PUFA被包封在乳品蛋白的玻璃状基质中,或可以以商品名“NIF粉末(NIF powder)”从佛里斯兰坎皮纳奇威公司(FrieslandCampina Kievit)购得。
如本文中所述,本发明的组合物还使用蔗糖铁,优选地高浓度蔗糖铁进行强化。本发明人惊奇地发现在本发明的组合物中使用蔗糖铁作为铁源,可防止通常由LC-PUFA和铁混合引起的异味的生成。与包含另一种铁源的类似组合物相比,蔗糖铁提供最佳感官特性,并且在本发明的组合物中,将本蔗糖铁与微胶囊包封的LC-PUFA混合时无显著异味,证明了没有出现明显的LC-PUFA氧化,优选地没有出现LC-PUFA氧化。
根据一个优选的方面,本发明的组合物中包含的蔗糖铁被微胶囊包封在藻酸盐基质中。这类藻酸盐基质可以是任何适用于技术人员制备包含蔗糖铁的微胶囊的藻酸盐基质。包封方法为技术人员所熟知。在本发明的情形中,蔗糖铁可被包封在如AB-Biotics公司的WO 2010/040789 A1中所述的藻酸盐基质中。或者,例如,包封在藻酸盐基质中的蔗糖铁可以以商品名AB-FORTIS从AB-Biotics公司购得。
在本发明的情形中,本发明的组合物中包含蔗糖铁以优选地提供一定量的铁,优选地为高含量的铁,占组合物的约0.0001重量%至约1重量%,优选地约0.001重量%至1重量%,更优选地约0.001重量%至0.1重量%。
根据另一个更优选的方面,本发明的组合物包含蛋白质源,所述蛋白质源优选地作为包封使用的蛋白质的附加成分包含在组合物中。
因此,根据一个优选的方面,本发明的组合物包含(附加的)蛋白质源,通常选自蔬菜或动物源,优选地来自乳品源。此外,溶液中可能存在蛋白质的级分或部分水解产物,优选地为本文所述的蛋白质的级分或部分水解产物。优选地,本发明的组合物单独包含乳品蛋白、更优选地乳清蛋白或同时包含乳品蛋白、更优选地乳清蛋白与选自蔬菜(例如大豆蛋白)或动物源的其他蛋白质,作为(附加的)蛋白质源。特别优选地,该蛋白质源是乳品蛋白,例如上文所定义,更优选地为乳清蛋白和/或酪蛋白酸盐,最优选地为乳清蛋白。例如,合适的乳清蛋白源选自例如:乳清蛋白、乳清分离蛋白(WPI)、酸化乳清分离蛋白、乳清蛋白浓缩物(WPC)、干酪乳清,更优选地为蛋白质/干物质含量为30%–89%的WPC、蛋白质/干物质含量为90%或更高的乳清分离蛋白(WPI)、乳清粉以及它们的组合等,可单独包含或同时包含。一般来讲,本发明的组合物可包含如上文所定义的天然或变性蛋白质、这类蛋白质的级分和/或(部分)水解产物或它们的混合物。
针对本发明的目的,本文定义的组合物优选地包含占组合物约0.1重量%至25重量%的蛋白质,优选地基于本发明的组合物中包含的蛋白质(除了用于包封的蛋白质)进行计算,更优选地基于本发明的组合物中包含的蛋白质(除了用于包封的蛋白质)进行计算包含约5重量%至15重量%的蛋白质,所述蛋白质优选地为乳清蛋白。
蛋白质的量通常由本领域的技术人员基于本发明的组合物的所需营养特性来进一步确定。例如,如果本发明的组合物是婴儿配方食品,则本发明的组合物优选地包含如本文中所述的蛋白质,所述蛋白质提供该组合物总能量的约4至约30%,更优选地8至20%。在另一个实施例中,如果本发明的组合物为成长乳,则本发明的组合物优选地包含如本文中所述的蛋白质,所述蛋白质提供该组合物总能量的约11至18%。
本发明人惊奇地发现,当本发明的组合物中包含乳清蛋白作为用于包封的蛋白质的附加成分时,这样甚至进一步防止或降低液体或粉末产品中LC-PUFA的氧化,乳清蛋白与LC-PUFA的微胶囊包封和蔗糖铁作为铁源的使用这一组合协同作用。
根据一个优选的方面,本发明的组合物包含碳水化合物源。本发明的组合物中包含的碳水化合物源通常可以选自任何合适的和并且优选地还起到甜味剂的作用的碳水化合物源。优选地,本发明的组合物中采用的碳水化合物源可优选地选自蔗糖(优选地细白砂糖)、果糖、麦芽糖糊精、纤维、玉米糖浆、高果糖玉米糖浆、玉米淀粉、乳糖、葡萄糖、右旋糖、麦芽糖以及它们的组合等,可单独包含或同时包含。
优选地,碳水化合物源提供本发明的组合物总能量的40至80%,但采用的碳水化合物的量可根据产品以及消费者的营养需求而改变。
衍生自碳水化合物或另外的来源的甜味剂可任选地使用,但这一点将取决于产品类型。
根据一个其他的优选方面,本发明的组合物包含脂肪源。特别优选地,所述组合物包含除LC-PUFA以外的其他类型的脂肪。这类脂肪可以是任何适合产品类型的脂肪。然而,已发现在存在非敏感性油,优选地为饱和或单不饱和脂肪酸的形式(例如中链甘油三酯(MCT))的情况下,可进一步改善稳定性,即防止或降低LC-PUFA氧化。因此,针对本发明的目的,还包含饱和和/或单不饱和脂肪酸源(优选地为MCT源)的组合物是优选的。
此外,根据一个优选的方面,本发明的组合物中包含的脂肪通常可选自任何合适的脂肪源,选自椰子油(优选地分馏椰子油)、柠檬油、膳食脂肪、植物油(例如向日葵油、优选地高油酸向日葵油、芥花油、玉米油、大豆油、芝麻籽油、红花油、核桃油、月见草油、花生油、棉花籽油、菜籽油、橄榄油、澳洲坚果油、棕榈油、棕榈仁油)或它们的混合物等,可单独包含或同时包含。针对本发明的目的,用作MCT源的脂肪是优选的。
根据本发明,脂肪优选地选自由单个碳原子连接成的2至24个碳原子长度的链组成的(脂肪)分子。
针对本发明的目的,本文所定义的组合物优选地包含占组合物约0.1重量%至约90重量%的脂肪,优选地占组合物约0.5至约10重量%,或约5至约15重量%,或约7至约30重量%,或约20至约60重量%,或约40至约80重量%,或约70至约85重量%。在上文中,术语“%”优选地定义为“重量%”,并且在本文上下文中指示脂肪的总量。
优选地,脂肪提供本发明的组合物总能量的5至40%,但采用的碳水化合物的量可根据产品以及消费者的营养需求而改变。
本发明中可使用的中链甘油三酯(MCT)通常包括6至10、或6至11、或6至12个碳的碳链。由于MCT具有较短的链长度,因此具有一些独特的特性,使它们优于更常见的LCT。本发明中采用的MCT优选地源于分馏椰子油、澳洲坚果油、棕榈油、棕榈仁油、乳脂肪等以及它们的组合。
本发明的组合物中可采用的油取决于产品类型进行选择。例如,对于基于乳的产品,乳脂肪将是优选的。
本发明的组合物中优选地包含诸如MCT的非敏感性油,因为本发明人惊奇地发现,MCT可防止或进一步降低LC-PUFA氧化并且通过降低由氧化生成的腥臭和油漆味的异味来改善感官特性,这类非敏感性脂肪与LC-PUFA的微胶囊包封和蔗糖铁作为铁源的使用这一组合协同作用。因此,MCT优选地包含在本发明的组合物中,因为这样可进一步防止或减弱LC-PUFA的异味。
本发明的组合物最优选地包含至少一种作为自由基清除剂的抗氧化剂,优选地为生育酚(维生素E),因为本发明人惊奇地发现,这种抗氧化剂可防止或进一步降低LC-PUFA氧化并且通过减弱由氧化生成的腥臭和油漆味的异味来改善感官特性,这类抗氧化剂与LC-PUFA的微胶囊包封和蔗糖铁作为铁源的使用这一组合协同作用。更有利的是,生育酚(维生素E)也具有营养效果。
最优选地,作为自由基清除剂的抗氧化剂占本发明的组合物约0.001重量%至约1重量%。优选地占组合物约0.005至约0.2重量%,或约0.1至约0.5重量%,或约0.3至约0.8重量%,或约0.6至约0.9重量%。
可选地,取决于本组合物的预期用途,本发明的组合物还可包含其他成分。这类成分可因为营养目的添加,例如微量营养素。或者,它们可因为技术原因添加,例如用于改善产品稳定性(例如乳化剂就是这种情况),或用于享乐目的。
针对本发明的组合物的目的,还可存在乳化剂,所述乳化剂可包括但不限于蛋白质、蛋白质水解产物。乳化剂还可选自食品级乳化剂,例如卵磷脂、单甘油酯和双甘油酯、蛋白质和糖酯,例如脱水山梨醇酯,脱水山梨醇可以(例如)以商品名Tween从不同的供应商处购得。
特别优选的乳化剂是脂肪酸的单甘油酯和/或双甘油酯,优选地为硬脂酸单甘油酯和/或硬脂酸双甘油酯。可采用多种来源的蛋白质或蛋白质水解产物;乳蛋白例如乳清蛋白和酪蛋白酸盐是优选的。
乳化剂还包括改性淀粉,例如Hi cap。这类改性淀粉例如可通过与n-辛烯基琥珀酸酐(NOSA)反应来进行改性。单甘酯和双甘酯、蒸馏单甘酯、蛋黄和卵磷脂,这些物质可单独存在或以组合形式存在。所述乳化剂存在的量可为本发明组合物重量的约0.05重量%至约1重量%,优选地约0.1重量%至约0.2重量%,或约0.15重量%至约0.3重量%,或约0.18重量%至约0.4重量%,或约0.35重量%至约0.5重量%,或约0.45重量%至约0.65重量%,或约0.55重量%至约0.8重量%,或约0.7重量%至约0.9重量%。
本发明的组合物中还可采用酸,优选采用柠檬酸和/或苹果酸和/或抗坏血酸和/或乳酸和/或琥珀酸和/或乙酸。酸可以液体或干燥性形式加入,例如以水合物或无水形式等加入。优选地,本发明的组合物具有中性或酸性pH。本发明的组合物优选地为半液体/半固体组合物,最优选地为液体组合物,该组合物的pH优选地被调节至约3.5至约7.5,更优选地被调节至约4至约7。
当产品为粉末形式并且旨在水中冲调时,pH是指产品用水冲调后的pH。
所述本发明组合物还可包含选自维生素、矿物质和痕量元素的微量营养素,这些微量营养素可单独存在或以组合形式存在。或者,在一些实施方案中,本发明的组合物还可不包含任何微量营养素。如本文所用,术语“微量营养素”是指人饮食中需要但需求量非常少的维生素和(膳食)矿物质。本发明的组合物中具体的维生素和矿物质的量通常可由本领域技术人员确定。
如本文所用,术语“维生素”是指需求量极少但对大多数动物的营养而言是必需的多种有机物质中的任一种,这类物质在调控代谢过程中特别作为辅酶和辅酶前体。维生素具有不同的生物化学功能,包括作为激素(例如维生素D)、抗氧化剂(例如维生素C和维生素E)以及细胞信号转导的介质、调控细胞生长、组织生长和分化(例如维生素A)的功能。数量最为庞大的B族维生素作为酶辅助因子生物分子(辅酶)的前体,可有助于在代谢中作为催化剂和底物。例如维生素B6和维生素B12。可存在的其他维生素包括维生素K、硫胺、核黄素、烟酸、叶酸、生物素和泛酸。可掺入这些维生素中的任一种,优选掺入维生素C和/或维生素E。
本发明的组合物中还可包含的膳食矿物质包括除碳、氢、氮、氧以外的化学元素,这些元素是维持活生物体健康所必需的。在人体中,膳食矿物质可包括钙、镁、磷、钾、钠和硫。优选地,本发明的组合物中包含钙,并且任选地还包含至少一种上述膳食矿物质。
此外,需求量相对较少并且可被称为痕量元素的矿物质包括例如铬、钴、铜、氯、氟、碘、锰、钼、硒和锌。
在本发明组合物的一些优选实施方案中不包含锌。
本文所述的本发明组合物可包含上述维生素、矿物质和痕量元素的任意组合,这些组合可用于为患者提供适当的营养。维生素、矿物质和痕量元素可以混合物或制剂的形式使用。
任选地,本发明的组合物还可包含益生菌、益生元、矿物质、增稠剂、缓冲剂或pH调节剂、螯合剂、着色剂、乳化剂、赋形剂、调味剂、渗透剂、防腐剂、稳定剂、糖、甜味剂、质构剂和/或维生素作为任选成分。例如,该组合物可包含乳化剂和稳定剂,例如大豆卵磷脂、柠檬酸单甘酯和柠檬酸双甘酯等。可以任何合适的量和类型添加这些任选成分,优选地如本文中所定义的方式进行添加。
在这个情形中,益生菌优选地被理解为食物级微生物(活的,包括半活的或弱化的,和/或非复制性的)、代谢物、微生物细胞制剂或微生物细胞成分,当以足够量施用时,它们可为宿主提供健康益处,更具体地讲,它们通过改善宿主肠内微生物平衡有益地影响宿主,从而影响宿主的健康或幸福。参见Salminen S.,et al.,“Probiotics:how should they be defined?”Trends Food Sci.107-10(1999)(Salminen S.等人,“如何定义益生菌?”,《食品科学与技术趋势》,1999年,第10卷,第107-110页)。一般来讲,据信这些微生物抑制或影响病原性细菌在肠道中的生长和/或代谢。益生菌还可激活宿主的免疫功能。
益生菌的非限制性例子包括气球菌属(Aerococcus)、曲霉属(Aspergillus)、拟杆菌属(Bacteroides)、双歧杆菌属(Bifidobacterium)、假丝酵母属(Candida)、梭菌属(Clostridium)、德巴利酵母属(Debaromyces)、肠球菌属(Enterococcus)、梭杆菌属(Fusobacterium)、乳杆菌属(Lactobacillus)、乳球菌属(Lactococcus)、明串球菌属(Leuconostoc)、蜜蜂球菌属(Melissococcus)、微球菌属(Micrococcus)、毛霉属(Mucor)、酒球菌属(Oenococcus)、片球菌属(Pediococcus)、青霉属(Penicillium)、消化链球菌属(Peptostrepococcus)、毕赤酵母属(Pichia)、丙酸杆菌属(Propionibacterium)、假链状菌属(Pseudocatenulatum)、根霉菌属(Rhizopus)、酵母菌属(Saccharomyces)、葡萄球菌属(Staphylococcus)、链球菌属(Streptococcus)、球拟酵母属(Torulopsis)、魏斯氏菌属(Weissella)或其组合。
在本发明的情形中,益生元优选地是一种食品物质,其选择性地促进有益细菌在肠道中的生长或者抑制病原性细菌在肠道中生长或粘附于肠道粘膜。它们不会在摄入它们的人的胃和/或肠上部中被失活或在胃肠道中被吸收,但是它们会被胃肠微生物群和/或被益生菌发酵。益生元(例如)由以下文献定义:Glenn Gibson et al.,“Dietary Modulation of the HumanColonic Microbiota:Introducing the Concept of Prebiotics,”J.Nutr.,125:1401-1412(1995)(Glenn Gibson等人,“人结肠微生物饮食调节:介绍益生元的概念”,《营养学杂志》1995年,第125卷,第1401-1412页)。
益生元的非限制性例子包括阿拉伯树胶、α-葡聚糖、阿拉伯半乳聚糖、β-葡聚糖、右旋糖酐、低聚果糖、岩藻糖基乳糖、低聚半乳糖、半乳甘露聚糖、低聚龙胆糖、低聚葡萄糖、瓜耳胶、菊粉、低聚异麦芽糖、乳糖新四糖(lactoneotetraose)、乳蔗糖、乳酮糖、果聚糖、麦芽糖糊精、乳寡糖、部分水解的瓜耳胶、果胶低聚糖、抗性淀粉、回生淀粉、唾液酸低聚糖、唾液酸乳糖、大豆低聚糖、糖醇、低聚木糖、或它们的水解产物、或它们的组合。
在一些实施方案中,本发明的组合物有利地进一步包含风味物成分,该风味物成分根据产品需求进行选择。在一些实施方案中,如果需要,风味物还可用作掩味剂,以更进一步改善组合物的感官特性,或可用于赋予该组合物更具吸引力的风味,特别在增加最终用户接受度的营养领域中。
此外,本发明的组合物可包含水。本发明的组合物中水存在的量可根据产品类型而不同,优选地,本发明的组合物中水存在的量为本发明组合物重量的约2重量%至约95重量%,或约3重量%至约10重量%,或约5重量%至约13重量%,或约11重量%至约20重量%,或约15重量%至约40重量%,或约30重量%至约50重量%,或约45重量%至约65重量%,或约60重量%至约80重量%,或约70重量%至约95重量%。水的量也可十分低,例如当组合物为粉末形式时。
如本文所述的组合物为固体(例如粉末)、液体或半液体/半固体,但特别优选的是液体,例如水包油乳剂。
在一个最优选的方面,本发明的组合物能够稳定液体或粉末产品中的LC-PUFA。液体或粉末产品中LC-PUFA的稳定优选地指抑制或至少显著降低LC-PUFA的氧化,使得相较于除了包含其他LC-PUFA和/或另一种铁源外包含相同成分的组合物,本组合物不具有由LC-PUFA氧化产物引起的异味或至少该异味减弱。这类异味可由技术人员根据公认的感官测试标准(例如偏好测试)进行测试和检验。
根据一个特别优选的实施方案,本发明的目的优选地通过一种组合物得到解决,该组合物通常包含:
LC-PUFA,优选地源于鱼油或藻油,最优选地源于鱼油,该LC-PUFA优选地包封在乳品蛋白和葡萄糖的玻璃状基质中。所述LC-PUFA优选地包含20mg至3g DHA和/或EPA/100g产品,通常带有包封的蔗糖铁,优选地蔗糖铁被包封在藻酸盐基质中。蔗糖铁存在的量优选地为0.1mg至1g/100g产品。本组合物优选地提供所述LC-PUFA和蔗糖铁,带有饱和及单不饱和脂肪/油,该饱和及单不饱和脂肪/油优选地包含量为0.1g至90g/100g产品的中链甘油三酯,带有自由基清除剂抗氧化剂,该抗氧化剂优选地是量为0.001g至1g/100g产品的维生素E,优选地带有量为0.1g至20g/100g产品的乳清蛋白。
优选地,本文中所定义的本发明的组合物可以是营养组合物、药物组合物和/或营养产品。根据一个优选的方面,本发明的组合物是营养组合物。
此外,本发明的组合物可用作补充剂或可用作唯一的营养源(例如作为全餐)。此外,本发明的组合物可适用于或被用于治疗本文中所定义的疾病,尤其是用作药剂。此外,本发明的组合物可优选地经过包装,该包装优选地提供施用单位或剂量。
本文中所定义的营养组合物优选地被设计和用于婴儿、儿童或成人。对于婴儿营养,本发明的营养组合物优选地为婴儿配方食品。对于成人营养,它被优选地用作孕产妇营养食物或衰老保健营养产品。或者,本发明的营养组合物可为医疗保健产品,优选地用于医疗保健营养,即预期用于病人特定营养的产品,该病人优选地患有如本文所定义的疾病或病症。
在本发明的情形中,婴儿在本文中优选地被定义为年龄最大至2岁,而儿童被定义为年龄2至7岁。
同样在本发明的情形中,孕产妇营养被优选地定义为用于怀孕和哺乳女性,此外还涵括预想施用给打算生小孩的女性。
同样在本发明的情形中,衰老保健营养优选地被定义为预期用于中老年人或用于想要降低衰老副作用的成人的产品。
优选地,营养组合物是食物基质、饮料或食物补充剂。例如,针对如本文所定义的儿童,可以成长乳的形式使用本发明。如本文所用,术语“食物补充剂”是指可添加到饮食或其一餐中的本发明组合物。
在本文中,营养组合物通常被定义为任何类型的呈液体或粉末形式的食物,其中在这个情形中,所述营养组合物通常包含蛋白质和/或脂肪和/或碳水化合物。蛋白质、脂肪和碳水化合物以及任何其他成分优选地如上文所定义,并且可根据在本发明组合物的情形中所述进行选择。
在本发明的情形中,蛋白质、脂肪和碳水化合物通常是本发明的营养组合物的营养成分,该营养成分根据产品类型进行选择。然而,只要产品类型可接受,脂肪应选择饱和或单不饱和脂肪/油,优选地选择MCT。另外,只要产品类型可行,优选使用乳清,至少用作部分蛋白质,如果可能,优选仅使用乳清。
优选地,可通过任何适于技术人员的方法得到本发明的组合物。更优选地,本发明的组合物可通过或能够通过本文所定义的制备组合物的方法获得。
因此,根据一个另外的实施方案,本发明的目的还优选地通过制备组合物的方法得到解决,该组合物优选地为如本文所定义的组合物。因此,本发明描述了如上所述的组合物,优选地描述了得自或能够得自根据如本文所定义的制备这类组合物的方法的组合物。就这一点而言,所述方法可包括或包含如针对本发明的组合物所定义的任何的量和成分。
根据一个特别优选的方面,本发明的目的通过制备组合物的方法得到解决,该组合物更优选地为如本文所述的组合物,该方法包括混合或干混如上文所定义的成分以获得混合物的步骤,该混合物最优选地为如本文所述的本发明组合物。
所述方法优选地还包括以下步骤
(a)对混合或干混成分后得到的所述混合物进行至少一个热处理步骤;以及
(b)优选地在该热处理步骤之前或之后均质化该混合物。
所述方法优选地在介于约3.5至约7.5之间的pH下进行,或将该混合物相应地优选地调节至如上文针对本发明的组合物所定义的pH。
如果所述方法中采用了酸,则可以液体或干燥形式加入该酸,例如以水合物或无水形式等加入。酸优选地为如上文所定义。
有利地,所述方法包括诸如热处理和均质化的步骤,这些步骤改善产品的安全性和质量。在本发明的组合物中,LC-PUFA有利地被稳定,使得即使进行所述方法的相对剧烈的热处理和均质化步骤时,也能防止氧化。因此,本发明的组合物保持了良好的感官特性,因为LC-PUFA在热处理和均质化期间的氧化受到限制。
本发明的方法优选地生成固体、液体或半液体/半固体组合物,最优选地生成液体组合物。因此,本发明的组合物还可作为固体组合物(例如粉末)或液体或半液体/半固体组合物存在。
当本发明的组合物为固体形式(例如粉末)时,该方法应优选地包括喷雾干燥、冷冻干燥或流化床团聚步骤。
根据另一个实施方案,本发明的目的还优选地通过用于防止或减少包含LC-PUFA和铁的组合物中LC-PUFA氧化的方法得到解决,该方法包括将LC-PUFA以微胶囊形式加入组合物以及将铁以蔗糖铁形式加入组合物,其中LC-PUFA优选地被微胶囊包封在乳品蛋白和葡萄糖的玻璃状基质中。包含LC-PUFA和铁的组合物,优选地为所得的包含LC-PUFA和铁的组合物,优选地如本文所定义。
LC-PUFA氧化的防止或降低如上文已针对本发明组合物所定义。
根据又一个实施方案,本发明的目的还优选地通过用于防止或减弱包含LC-PUFA和铁的组合物中LC-PUFA异味的方法得到解决,该方法包括将LC-PUFA以微胶囊形式加入组合物以及将铁以蔗糖铁形式加入组合物,其中LC-PUFA优选地被微胶囊包封在乳品蛋白和葡萄糖的玻璃状基质中。最优选地,这类组合物的成分如上文针对本发明组合物所述。所得的包含LC-PUFA和铁的组合物优选地如本文所定义。
防止或减弱LC-PUFA异味被定义为相较于除了包含其他LC-PUFA和/或另一类铁源外包含相同成分的组合物,防止或减弱诸如酸败、腥臭、金属味、油漆味、油煎等异味。这类异味可由技术人员根据公认的感官测试标准(例如偏好测试)进行测试和检验。
根据另一个实施方案,设想了如本文所述的本发明组合物的用途,无论是初始描述的还是根据本发明的方法获得或能够获得的本发明组合物。本发明的组合物特别适用于如本文所定义的疾病或病症的膳食管理中,或用于食物强化。
如本文所用,术语“强化”还包括向食物或营养组合物中加入整体饮食中可能缺乏的营养物质,优选地在如本文所述的本发明方法中加入。这些营养物质包括但不限于:叶酸、维生素A和维生素D,优选地作为氧清除剂的维生素C、钙或如本文所述的用于本发明组合物的任何其他营养物质,特别是如本文所述的LC-PUFA和铁。
优选地,本发明的组合物,优选地通过如本文所述的制备组合物的方法获得或能够获得的本发明组合物,可用于预防、改善或治疗如本文所定义的疾病或病症。如本文所用,术语“病症”或“疾病”是指功能的任何紊乱或异常;病变躯体或精神状态。参见Dorland's Illustrated MedicalDictionary,(W.B.Saunders Co.27th ed.1988)(《道兰图解医学词典》,W.B.桑德斯公司,第27版,1988年)。这些疾病或病症可选自营养不良、代谢疾病、神经退行性疾病、阿尔茨海默病/认知功能障碍、帕金森氏病、神经系统疾病、肌萎缩性脊髓侧索硬化症、外伤性脑损伤、缺氧性/缺血性脑损伤、自闭症、ADHD(注意力缺陷多动障碍)、抑郁症、头痛、偏头痛、发作性嗜睡病、GLUT-1缺乏症、丙酮酸脱氢酶(PDH)缺乏症、磷酸果糖激酶(PFK)缺乏症、V型糖原累积病(麦卡德尔病)、心肌缺血、Rett综合征、结节性硬化症、糖尿病和癌症(星型细胞瘤、前列腺癌、胃癌、肾癌、头颈癌),优选地用于预防、改善或治疗营养不良、代谢疾病、神经退行性疾病,优选地作为营养补充剂。该组合物优选地用作营养组合物或补充剂。
本发明的组合物还可用于促进神经系统和/或视网膜的发育,以及/或者促进和/或改善婴儿或儿童的精神表现、行为和视觉功能。
出于本发明的目的,精神表现是指诸如婴儿或儿童的认知和智力表现、记忆力以及语言能力。神经系统发育旨在包括诸如大脑和神经元发育。
本发明的组合物可进一步用于增强免疫力,包括发展肠道菌群。
此外,本发明的组合物还可用于降低发生超重、肥胖和胰岛素抗性的风险。
如上文所述的本发明组合物的有利效果,优选地通过将有效量的根据本发明的组合物施用给有需要的受试者来实现。优选地,这类组合物按一天一次施用,优选地一天两次,更优选地一天三次,其中施用时,优选地提供至少一个如本文所定义的施用单位或剂量。在施用时,每天要施用的总能量值优选地如上文所定义。如本文所用,术语“受试者”是指动物。优选地,该动物是哺乳动物。受试者还指诸如灵长类(例如人)、奶牛、绵羊、山羊、马、狗、猫、兔、大鼠、小鼠、鱼、鸟等。在一个优选的实施方案中,受试者是人,更优选地选自婴儿、儿童或成人。术语“有效量”的本发明组合物是指将引起受试者产生生物或医学响应、增强受试者发育或器官或功能、改善症状、延缓或延迟疾病进程或预防疾病等的本发明化合物的量。优选地这种“有效量”是如本文所述所获得的包装剂量或单位。
特别优选地,如本文所述的本发明组合物(无论是初始描述的还是根据本发明方法获得或能够获得的本发明组合物)优选地适用于婴儿,例如用于如本文所定义的营养、补充营养或疾病治疗。然而,本发明还适用于成人和儿童,优选地用于如本文所定义的营养、补充营养或疾病治疗。
本发明还包括治疗方法,该治疗方法针对如本文所定义的疾病或病症对有需要的患者施用如本文所定义的组合物。
本发明的治疗方法中使用的组合物最优选的是固体、液体或半液体/半固体,甚至更优选的是液体。
在所述本发明的治疗方法中,本发明的组合物优选地为补充剂形式。作为另外一种选择,优选的是,在所述治疗方法中,本发明的组合物用作如本文所定义的营养的唯一来源。
在本发明的治疗方法中特别优选的是,优选地为固体、半液体/半固体组合物、最优选地为液体组合物的该组合物被调节至中性或酸性pH,优选地被调节至介于约3.5至约7.5之间的pH,优选地介于约4至约7之间的pH或根据上文所述的范围的pH。
上文描述了本发明的多个实施方案。这些描述是说明性的,而非限制性的。因此,对本领域技术人员显而易见的是,可在不脱离所附权利要求书的范围的情况下对所述的本发明作出某些修改。
除非另外指明,本发明上下文中通常在一系列元素之前的术语“至少”应被理解为是指该系列中的每个元素。本领域技术人员将认识到或仅使用常规实验就能够确定本文所述本发明的具体实施方案的许多等同方案。这些等同方案旨在涵盖在本发明中。
例如,如本文所述,“优选的实施方案”是指“本发明的优选实施方案”。同样,如本文所述,“多个实施方案”和“另一个实施方案”分别指“本发明的多个实施方案”和“本发明的另一个实施方案”。
纵观本说明书以及随后的权利要求书,除非语境另有要求,否则词语“包括”以及诸如“包含”和“含有”等变体词语应被理解为表示包含所提到的完整物(integer)或步骤或者完整物或步骤的组,但不排除任何其他完整物或步骤或者完整物或步骤的组。在本文中使用时,术语“包含”可用术语“含有”替代,或有时在本文中使用时,可用术语“具有”替代。在本文中使用时,“由…组成”不包括任何在权利要求要素中没有指定的要素、步骤或成分。在本文中使用时,“基本上由…组成”不排除不会实质性地影响权利要求的基本特征和新特征的材料或步骤。在本文中的各个例子中,术语“包含”、“基本上由…组成”和“由…组成”可与其他两个术语中的任一个替换使用。
此外,如果没有另外特别说明,则本发明中所描述的百分比可互换地为重量/重量百分比(w/w)或重量/体积百分比(w/v)。
最后,本公开中引用的所有出版物和专利均全文以引用方式并入本文。如果以引用方式并入的材料与本说明书矛盾或不一致,则本说明书将优先于任何这类材料。
实施例:
以下实施例旨在进一步说明本发明。这些实施例不旨在将本发明的主题限制在这些实施例中。
实施例1:
在pH 7和pH 4下制备测试乳剂。在两种pH下,在存在或不存在中链甘油三酯(MCT)的情况下,将下表中提到的鱼油形式(未包封或包封的)与
-下表中提到的每种铁形式,
-下表中提到的每种蛋白质以及
-下表中提到的每种抗氧化剂,
相结合,制备乳剂。
下表1和表2列出了测试乳剂中使用的成分及其对应的量。
表1:pH 7下的实验设计
1)包含约30%DHA和EPA的纯鱼油
2)微胶囊包封在乳品蛋白和葡萄糖的玻璃状基质中的LC-PUFA
3)包封在藻酸盐基质(AB-Fortis)中
5)包含60%DHA和EPA的浓缩鱼油
表2:pH 4下的实验设计
1)包含约30%DHA和EPA的纯鱼油
2)微胶囊包封在乳品蛋白和葡萄糖的玻璃状基质中的LC-PUFA
3)包封在藻酸盐基质(AB-Fortis)中
4)含双层交联明胶的乳剂
5)包含60%DHA和EPA的浓缩鱼油
使用以下方法制备乳剂。在室温下将鱼油、MCT(如果存在)、乳化剂和维生素E(如果存在)混合。然后将该混合物在水中分散,并加入蛋白质、维生素C(如果存在)和铁。使用ultraturrax分散机在12000U/分钟下对所得乳剂均质6分钟。然后通过加入柠檬酸将pH调节为pH 7或pH4。再使用微型均质机在400bar和600bar(代表台式均质机的较低压力值)均质该乳剂。然后热处理该乳剂(80℃,30秒)。再将该乳剂装入无菌的塑料容器中。
然后由经过培训的专业小组(10至12人)对每份乳剂进行感官评估。小组成员在乳剂制备好一天后品尝乳剂。以0至5范围的量度(5为鱼腥味/油漆味最强,0为无气味或无味道)来评估鱼腥气味、鱼腥味道、油漆气味和油漆味道。品尝会议在独立的实验台和环境温度下进行。然后使用统计方法估测每种成分对鱼腥味道和气味以及油漆味道和气味的贡献。
由于针对“鱼腥气味”的感官数据与“鱼腥味道”具有完全相同的趋势并且针对“油漆气味”的感官数据与“油漆味道”具有完全相同的趋势,因此我们在此部分只选择说明“鱼腥味道”和“油漆味道”的结果。
相较于未包封的鱼油,微胶囊形式的鱼油显示具有减弱的异味。在pH7和pH 4下,鱼腥和油漆异味方面表现最好的鱼油都是NIF粉末7。在pH7下,鱼腥和油漆异味方面表现最好的铁形式是焦磷酸铁和包封在藻酸钙基质(购自AB Fortis)中的蔗糖铁。这两种铁形式得到了与不含铁的变体相同的异味强度。在pH 4下,只有包封在藻酸钙基质中的蔗糖铁具有减弱鱼腥和油漆异味的作用。微胶囊包封的鱼油(最尤其指NIF粉末7)和蔗糖铁的结合在针对鱼腥和油漆味道的异味减弱方面给出了最佳结果。
在pH 7下,在鱼腥和油漆异味方面表现最好的蛋白质是乳清蛋白。在pH 7和pH 4下,在存在中链甘油三酯(MCT)时,油漆味和鱼腥味方面的感官得分均更好。
已证明使用抗氧化剂可有效地进一步减弱油漆和鱼腥异味。在pH 7和pH 4下的乳剂中,在鱼腥和油漆异味方面表现最好的抗氧化剂是生育酚(维生素E)。
Claims (16)
1.一种使用蔗糖铁和高浓度微胶囊包封的LC-PUFA进行强化的组合物。
2.根据权利要求1所述的组合物,其中所述LC-PUFA的量为所述组合物的约0.02重量%至10重量%。
3.根据前述权利要求中任一项所述的组合物,其中所述LC-PUFA被微胶囊包封在乳品蛋白和葡萄糖的玻璃状基质中,所述LC-PUFA优选地源于鱼油或藻油。
4.根据前述权利要求中任一项所述的组合物,其中所包含的蔗糖铁提供的铁含量占所述组合物的约0.0001重量%至1重量%。
5.根据前述权利要求中任一项所述的组合物,其中所述蔗糖铁被微胶囊包封,优选地被微胶囊包封在藻酸盐基质中。
6.根据前述权利要求中任一项所述的组合物,所述组合物包含至少一种为自由基清除剂的抗氧化剂,优选地为生育酚(维生素E)。
7.根据前述权利要求中任一项所述的组合物,所述组合物包含非敏感性脂肪,优选地为饱和脂肪或单不饱和脂肪,最优选地包含中链甘油三酯。
8.根据前述权利要求中任一项所述的组合物,所述组合物为食物基质、饮料或食物补充剂。
9.根据权利要求8所述的组合物,其中所述食物产品是营养组合物,
优选地用于婴儿、儿童、孕产妇或医疗保健营养。
10.根据前述权利要求中任一项所述的组合物,所述组合物为药物组合物和/或营养产品。
11.根据权利要求1至10中任一项所述的组合物,所述组合物用于预防、改善或治疗营养不良、代谢疾病、神经退行性疾病,所述组合物优选地作为营养补充剂。
12.根据权利要求1至10中任一项所述的组合物,所述组合物用于促进神经系统和/或视网膜发育,用于促进和/或改善婴儿或儿童的精神表现、行为和视觉功能,用于加强免疫力,包括发展肠道菌群,以及/或者用于降低发生超重、肥胖和胰岛素抗性的风险。
13.一种用于防止或减少包含LC-PUFA和铁的组合物中LC-PUFA氧化的方法,所述方法包括将LC-PUFA以微胶囊形式加入所述组合物以及将铁以蔗糖铁形式加入所述组合物,其中所述LC-PUFA优选地被微胶囊包封在乳品蛋白和葡萄糖的玻璃状基质中。
14.一种用于防止或减少包含LC-PUFA和铁的组合物中LC-PUFA异味的方法,所述方法包括将LC-PUFA以微胶囊形式加入所述组合物以及将铁以蔗糖铁形式加入所述组合物,其中所述LC-PUFA优选地被微胶囊包封在乳品蛋白和葡萄糖的玻璃状基质中。
15.根据权利要求22所述的方法,其中所得的组合物如根据权利要求1至10中任一项所定义。
16.一种用于制备根据权利要求1至10中任一项所述组合物的方法,所述方法包括混合或干混根据权利要求1至10中任一项所定义的成分的步骤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13199681.1 | 2013-12-27 | ||
EP13199681 | 2013-12-27 | ||
PCT/EP2014/078909 WO2015097113A1 (en) | 2013-12-27 | 2014-12-19 | Composition comprising ferric saccharate and high concentrations of microencapsulated lc-pufa with a reduced off taste |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105828642A true CN105828642A (zh) | 2016-08-03 |
Family
ID=49918477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480069674.5A Withdrawn CN105828642A (zh) | 2013-12-27 | 2014-12-19 | 包含蔗糖铁和高浓度微胶囊包封的lc-pufa且异味减弱的组合物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20160310596A1 (zh) |
EP (1) | EP3086654A1 (zh) |
JP (1) | JP2017503790A (zh) |
CN (1) | CN105828642A (zh) |
AU (1) | AU2014372631B2 (zh) |
CA (1) | CA2931222A1 (zh) |
MX (1) | MX2016008287A (zh) |
PH (1) | PH12016501111A1 (zh) |
RU (1) | RU2666190C2 (zh) |
WO (1) | WO2015097113A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111526737A (zh) * | 2017-12-28 | 2020-08-11 | 雀巢产品有限公司 | 包含一水硫酸亚铁和长链多不饱和脂肪酸的组合物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019008785A2 (pt) | 2016-12-15 | 2019-07-16 | Nestec Sa | composição em forma de pó que compreende complexos de ferro-caseína e compostos sensíveis à oxidação |
US20210093578A1 (en) * | 2017-04-27 | 2021-04-01 | Clover Corporation Limited | Encapsulated nutritional and pharmaceutical compositions |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5601760A (en) * | 1994-09-01 | 1997-02-11 | The Regents Of The University Of California, A California Corporation | Milk derived whey protein-based microencapsulating agents and a method of use |
CN1202804A (zh) * | 1995-10-27 | 1998-12-23 | 普罗克特和甘保尔公司 | 颜色稳定的,铁、锌、和维生素强化的混合饮料粉 |
CN1345588A (zh) * | 2000-09-29 | 2002-04-24 | 国家海洋药物工程技术研究中心 | 无腥鱼油复合微胶囊及其制备方法 |
US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
US20040224032A1 (en) * | 1998-02-27 | 2004-11-11 | Ped-Med Ltd. | Composition comprising micro-encapsulated iron |
CN1321584C (zh) * | 2000-04-04 | 2007-06-20 | 联邦科学和工业研究组织 | 食品成分的包封 |
WO2007107501A1 (en) * | 2006-03-21 | 2007-09-27 | Akzo Nobel N.V. | Double-fortified salt and preparation process therefor |
CN104522318A (zh) * | 2014-12-22 | 2015-04-22 | 新奥(厦门)农牧发展有限公司 | 一种提高富集ω3肉蛋奶的微胶囊脂肪粉及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE434391T1 (de) * | 1997-04-29 | 2009-07-15 | Procter & Gamble | Farbstabile mit eisen angereicherte trockene getränkemischungen,trinkfertige getränke und andere nahrungsmittel als getränke die gegebenenfalls zink enthalten |
TW200820913A (en) * | 2006-08-25 | 2008-05-16 | Martek Biosciences Corp | Food fortification with polyunsaturated fatty acids |
RU2007129979A (ru) * | 2007-08-06 | 2009-02-20 | Федеральное государственное образовательное учреждение высшего профессионального образовани Кубанский государственный аграрный университет (RU) | Железосодержащее средство для профилактики и лечения анемии |
EP2174657A1 (en) * | 2008-10-08 | 2010-04-14 | AB-Biotics Producciones Industriales De Microbiotas, S.L. | Iron source product in the form of capsules and process for their prepartion |
-
2014
- 2014-12-19 RU RU2016130803A patent/RU2666190C2/ru not_active IP Right Cessation
- 2014-12-19 CA CA2931222A patent/CA2931222A1/en not_active Abandoned
- 2014-12-19 JP JP2016541526A patent/JP2017503790A/ja active Pending
- 2014-12-19 AU AU2014372631A patent/AU2014372631B2/en not_active Ceased
- 2014-12-19 MX MX2016008287A patent/MX2016008287A/es unknown
- 2014-12-19 CN CN201480069674.5A patent/CN105828642A/zh not_active Withdrawn
- 2014-12-19 WO PCT/EP2014/078909 patent/WO2015097113A1/en active Application Filing
- 2014-12-19 US US15/107,541 patent/US20160310596A1/en not_active Abandoned
- 2014-12-19 EP EP14815387.7A patent/EP3086654A1/en not_active Withdrawn
-
2016
- 2016-06-10 PH PH12016501111A patent/PH12016501111A1/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
US5601760A (en) * | 1994-09-01 | 1997-02-11 | The Regents Of The University Of California, A California Corporation | Milk derived whey protein-based microencapsulating agents and a method of use |
CN1202804A (zh) * | 1995-10-27 | 1998-12-23 | 普罗克特和甘保尔公司 | 颜色稳定的,铁、锌、和维生素强化的混合饮料粉 |
US20040224032A1 (en) * | 1998-02-27 | 2004-11-11 | Ped-Med Ltd. | Composition comprising micro-encapsulated iron |
CN1321584C (zh) * | 2000-04-04 | 2007-06-20 | 联邦科学和工业研究组织 | 食品成分的包封 |
CN1345588A (zh) * | 2000-09-29 | 2002-04-24 | 国家海洋药物工程技术研究中心 | 无腥鱼油复合微胶囊及其制备方法 |
WO2007107501A1 (en) * | 2006-03-21 | 2007-09-27 | Akzo Nobel N.V. | Double-fortified salt and preparation process therefor |
CN104522318A (zh) * | 2014-12-22 | 2015-04-22 | 新奥(厦门)农牧发展有限公司 | 一种提高富集ω3肉蛋奶的微胶囊脂肪粉及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111526737A (zh) * | 2017-12-28 | 2020-08-11 | 雀巢产品有限公司 | 包含一水硫酸亚铁和长链多不饱和脂肪酸的组合物 |
Also Published As
Publication number | Publication date |
---|---|
RU2016130803A3 (zh) | 2018-07-03 |
PH12016501111A1 (en) | 2016-08-15 |
MX2016008287A (es) | 2016-09-08 |
EP3086654A1 (en) | 2016-11-02 |
RU2666190C2 (ru) | 2018-09-06 |
AU2014372631A1 (en) | 2016-05-26 |
AU2014372631B2 (en) | 2017-12-14 |
US20160310596A1 (en) | 2016-10-27 |
JP2017503790A (ja) | 2017-02-02 |
CA2931222A1 (en) | 2015-07-02 |
WO2015097113A1 (en) | 2015-07-02 |
RU2016130803A (ru) | 2018-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9107429B2 (en) | Emulsifier composition for shortening | |
Palzer | Food structures for nutrition, health and wellness | |
JP2021107394A (ja) | 栄養製品 | |
CN104822279A (zh) | 缓减压力症状的人乳寡糖 | |
CN105025734A (zh) | 含有富含脂质的部分的营养组合物及其用途 | |
CN105188417B (zh) | 包括β‑羟基‑β‑甲基丁酸钙、酪蛋白磷酸肽和蛋白质的营养组合物 | |
CN105744846A (zh) | 具有相对较高脂质含量的液体乳强化剂组合物 | |
CN106715381A (zh) | 用于用脂肪酸强化营养产品的脂肪酸组合物和方法 | |
JP2021168660A (ja) | 鉄−カゼイン錯体及び酸化感受性化合物を含む粉末形態の組成物 | |
Ahmad et al. | Fortification in beverages | |
TW201444480A (zh) | 包含結構性脂肪球之營養組成物及其用途 | |
CN105828642A (zh) | 包含蔗糖铁和高浓度微胶囊包封的lc-pufa且异味减弱的组合物 | |
JP2013515499A (ja) | ドコサヘキサエン酸を含む果実フレークを含む栄養組成物 | |
Rodríguez-Pérez et al. | New trends and perspectives in functional dairy-based beverages | |
CN106720333A (zh) | 含有dha和epa的发酵乳及其制备方法 | |
CN104703487B (zh) | 被包封的苦味肽、包封苦味肽的方法以及包含被包封的苦味肽的营养组合物 | |
Shahidi et al. | Beverages fortified with omega-3 fatty acids, dietary fiber, minerals, and vitamins | |
Cheng et al. | Functional butter for reduction of consumption risk and improvement of nutrition | |
JP2015510400A (ja) | ミルク様飲料を製造するための方法 | |
TW201141466A (en) | Methods of modulating inflammation in preterm infants using carotenoids | |
Marsanasco et al. | Liposomes as matrices to hold bioactive compounds for drinkable foods: their ability to improve health and future prospects | |
Panse et al. | Omega-3 beverages | |
Slozhenkina et al. | Functional fermented milk whey product: assessment of quality and safety | |
Honcharov et al. | Development of fermentation parameters of milk-fat mixtures in the production of sour cream product with phytosterols | |
RU2482704C2 (ru) | Питательная эмульсия (варианты) и способ приготовления питательной эмульсии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190702 Address after: Vevey Applicant after: SOCIETE DES PRODUITS NESTLE S. A. Address before: Vevey Applicant before: Nestle Products Technical Assistance Co., Ltd. |
|
TA01 | Transfer of patent application right | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160803 |
|
WW01 | Invention patent application withdrawn after publication |